Nancy J. Hutson - 05 Nov 2021 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc

Role: Director
Signature: /s/ John P. Sharp, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 05 Nov 2021
Net transactions value: $0
Form type: 4
Filing time: 08 Nov 2021, 17:26:09 UTC
Previous filing: 02 Nov 2021
Next filing: 20 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PHASQ	Common Stock	Options Exercise	$56,184	+24,860		$2.26^*	24,860	05 Nov 2021	Direct
transaction	PHASQ	Common Stock	Options Exercise	$4,725	+1,500	+6%	$3.15^*	26,360	05 Nov 2021	Direct
transaction	PHASQ	Common Stock	Options Exercise	$23,310	+7,400	+28%	$3.15^*	33,760	08 Nov 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PHASQ	Non-employee Director Stock Option (right to buy)	Options Exercise	$56,184	-24,860	-92%	$2.26^*	2,256	05 Nov 2021	Common Stock	24,860	$2.26	Direct	F1
transaction	PHASQ	Non-employee Director Stock Option (right to buy)	Options Exercise	$4,725	-1,500	-17%	$3.15^*	7,400	05 Nov 2021	Common Stock	1,500	$3.15	Direct	F2
transaction	PHASQ	Non-employee Director Stock Option (right to buy)	Options Exercise	$23,310	-7,400	-100%	$3.15^*	0	08 Nov 2021	Common Stock	7,400	$3.15	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option shall vest with respect to 25% of the shares on February 21, 2019, and shall vest in 36 additional monthly installments thereafter, subject to the reporting person's continued service through each such date.
F2	The shares subject to the option shall vest in equal monthly installments over 36 months from October 17, 2018, subject to the reporting person's continued service through each such date.